Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chantix for Vaping Cessation
NCT04317300Phase 1Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Feb 2023
- Primary completion
- Feb 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of varenicline in nicotine dependence, sponsored by Mayo Clinic. Primary endpoint: Rate of e-cigarette abstinence at 12 weeks. Planned start Feb 2023; status: withdrawn.
02
Drugs
varenicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT04317300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04317300.